Caladrius Biosciences to Host 2016 Second Quarter Financial Results Conference Call on August 9 at 5:00 pm Eastern Time
August 02 2016 - 7:30AM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the
“Company”), a cell therapy company combining an industry-leading
development and manufacturing services provider (PCT) with a select
therapeutic development pipeline, announces today that the Company
will release financial results for the second quarter of 2016 after
the U.S. financial markets close on Tuesday, August 9, 2016.
Caladrius’ management will host a conference call for the
investment community beginning at 5:00 pm ET on Tuesday, August 9,
2016, to discuss the financial results, provide a company update
and answer questions.
Shareholders and other interested parties may participate in the
conference call by dialing 877-562-4460 (U.S.) or 513-438-4106
(international) and providing conference ID 95709219. The call will
also be broadcast live on the Internet via the Company’s website at
www.caladrius.com/events. The webcast will be archived on the
Company’s website for 90 days.
About Caladrius Biosciences Caladrius
Biosciences, Inc., through its subsidiary, PCT, is a leading
development and manufacturing partner to the cell therapy
industry. PCT works with its clients to overcome the
fundamental challenges of cell therapy manufacturing by providing a
wide range of innovative services including product and process
development, GMP manufacturing, engineering and automation, cell
and tissue processing, logistics, storage and distribution, as well
as expert consulting and regulatory support. PCT and Hitachi
Chemical Co., Ltd. have entered into a strategic global
collaboration to accelerate the creation of a global commercial
cell therapy development and manufacturing enterprise with deep
engineering expertise. Around the core expertise of PCT,
Caladrius strategically develops select product candidates, which
currently includes an innovative therapy for type 1 diabetes based
on a proprietary platform technology for immunomodulation. For more
information, visit www.caladrius.com.
Forward Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management’s current expectations, as of the
date of this press release, and involve certain risks and
uncertainties. All statements other than statements of historical
fact contained in this press release are forward-looking
statements. The Company’s actual results could differ materially
from those anticipated in these forward-looking statements as a
result of various factors. Factors that could cause future results
to materially differ from the recent results or those projected in
forward-looking statements include the “Risk Factors” described in
the Company’s Annual Report on Form 10-K filed with the Securities
and Exchange Commission (“SEC”) on March 15, 2016, and in the
Company’s other periodic filings with the SEC. The Company’s
further development is highly dependent on, among other things,
future medical and research developments and market acceptance,
which are outside of its control.
CONTACTS:
Investors:
LHA Investor Relations
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-8377
Email: afields@lhai.com
Media:
Caladrius Biosciences, Inc.
Eric Powers
Director, Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024